The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > BUSINESS
BUSINESS
- Xtandi Significantly Extends OS, Lowers Risk of Death by 23%
March 26, 2015
- Santen Ups FY2014 Financial Outlook on Merck Asset Acquisition
March 26, 2015
- Sun Pharma Completes Merger with Ranbaxy; Daiichi Sankyo Owns 9% Share in Combined Firm
March 26, 2015
- Yoshiki Ito to Lead Merged Entity of Allergan, Actavis in Japan
March 25, 2015
- 3-Bracket Pricing Rule for Generics Should Be Defended: Sawai Chairman
March 25, 2015
- Takeda to Collaborate with ImmunoGen for ADC Technology
March 25, 2015
- Investigational Duchenne Muscular Dystrophy Drug Shows Favorable Results: Nippon Shinyaku, NCNP
March 25, 2015
- AZ Looks to Lead Industry in Immuno-Oncology Arena: Oncology Head
March 24, 2015
- Opdivo Wins South Korean Approval: Ono
March 24, 2015
- Takeda to Set Up Japan Oncology, Vaccine Business Units as Part of Corporate Reorganization
March 24, 2015
- Merck KGaA Gauging Regional Priorities for PD-L1 Inhibitor Development: Exec
March 24, 2015
- Amgen Astellas Seeks Japan Approval of PCSK9 Inhibitor
March 23, 2015
- Pfizer Japan Voluntarily Recalls Generic Gemcitabine
March 23, 2015
- Opicapone Reduces Off-Time by 2 Hours in Parkinson’s Disease Patients as Add-On to Levodopa: Ono
March 20, 2015
- Daiichi Sankyo, AZ to Copromote Constipation Treatment Movantik in US
March 20, 2015
- Astellas Files Kiklin to Treat Non-Dialysis CKD Patients
March 18, 2015
- MSD Revving Up Detailing on Rotavirus, Hepatitis B Vaccines, Eyes Public Immunization Program
March 18, 2015
- Alirocumab Meets Primary Efficacy Endpoint in PIII Study: Sanofi
March 17, 2015
- Minophagen Seeks Approval for CTCL Treatment
March 17, 2015
- Selexipag Lowers Risk of Morbidity, Mortality Events by 40% in PIII Study
March 17, 2015
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…